Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
Industry Pharmaceutical
Founded 1983
Headquarters Hinjwadi, Pune, India
Key people
 Satish Mehta [1] CEO
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
Number of employees
 over 9000
Slogan Success through Innovation
Website www.emcure.co.in

Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Indian plants

US plant

USA - The company has a manufacturing facility and R&D centre at East Brunswick, New Jersey, USA.

Capital markets

Emcure is planning to raise money through an initial public offering [2]

Recalls

There have been cases of drug recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recalls three batches of an anti-bacterial product from the US market due to presence of Penicillium Chrysogenum in some samples.[3] Teva recalls several batches of two products due to white tablets showing discoloration and presence of foreign particles in 2011 [4]

AIDS Initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [5] and Gilead Sciences for Tenofovir [6] as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. This is the first time that an Indian company has won a biological drug manufacturing contract.[7] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[8] The monthly doses priced at around $3000 are expected to be slashed significantly for wider access to cancer therapy.

Group Companies

References

  1. ↑ http://investing.businessweek.com/businessweek/research/stocks/private/person.asp?personId=23350262&privcapId=21771338&previousCapId=671980&previousTitle=BLACKSTONE%20GROUP%20LP/THE
  2. ↑ http://www.moneycontrol.com/news/ipo-upcoming-issues/emcure-pharma-plans-rs-700-crore-ipo_534950.html
  3. ↑ http://articles.economictimes.indiatimes.com/2010-11-11/news/27610085_1_pfizer-american-drug-regulator-manufacturing-norms
  4. ↑ http://www.recalls.org/d2011-03.htm
  5. ↑ http://www.business-standard.com/india/news/bristol-myers-outsources-aids-drug-to-emcure/233222/
  6. ↑ http://findarticles.com/p/news-articles/times-of-india-the/mi_8012/is_20060818/gilead-inks-offer-tenofovir/ai_n39427224/
  7. ↑ http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal
  8. ↑ http://www.businessworld.in/businessworld/businessworld/content/Roche-Sell-Cheaper-Cancer-Drugs-India.html?print=yes

External links